<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        45-271-19
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2019
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        DIAPHAGE 1 G SR TABLET
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        METFORMIN HYDROCHLORIDE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        1000
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        28
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        23.8
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="UNITED PHARMACEUTICAL COMPANY" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            UNITED PHARMACEUTICAL COMPANY
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 359]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Cigalah Group
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            UNITED PHARMACEUTICAL CO.
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        A10BA02
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Diaphage<sup>&reg;</sup></strong> SR prolonged release tablets contain the active ingredient metformin hydrochloride and belong to a group of medicines called biguanides, used in the treatment of Type 2 (non-insulin dependent) diabetes mellitus. <strong>Diaphage<sup>&reg;</sup></strong> SR is used together with diet and exercise to lower the risk of developing Type 2 diabetes in overweight adults, when diet and exercise alone for 3 to 6 months have not been enough to control blood glucose (sugar). You are at high risk of developing Type 2 diabetes if you have additional conditions like high blood pressure, age above 40 years, an abnormal amount of lipids (fat) in the blood or a history of diabetes during pregnancy.</p><p>The medicine is particularly effective if you are aged below 45 years, are very overweight, have high blood glucose levels after a meal or developed diabetes during pregnancy.</p><p><strong>Diaphage<sup>&reg;</sup></strong> SR is used for the treatment of Type 2 diabetes when diet and exercise changes alone have not been enough to control blood glucose (sugar). Insulin is a hormone that enables body tissues to take glucose from the blood and to use it for energy or for storage for future use. People with Type 2 diabetes do not make enough insulin in their pancreas or their body does not respond properly to the insulin it does make. This causes a buildup of glucose in the blood which can cause a number of serious long-term problems so it is important that you continue to take your medicine, even though you may not have any obvious symptoms.</p><p><strong>Diaphage<sup>&reg;</sup></strong> SR makes the body more sensitive to insulin and helps return to normal the way your body uses glucose. <strong>Diaphage<sup>&reg;</sup></strong> SR is associated with either a stable body weight or modest weight loss.</p><p>&nbsp;<strong>Diaphage<sup>&reg;</sup></strong> SR Prolonged Release Tablets are specially made to release the drug slowly in your body and therefore are different to many other types of tablet containing metformin.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Do not take <strong>Diaphage<sup>&reg;</sup></strong> SR if:</p><p>you are allergic to metformin or to any of the other ingredients of this medicine (listed in section 6). An allergic reaction may cause a rash, itching or shortness of breath.</p><p>you have liver problems</p><p>you have severely reduced kidney function</p><p>you have uncontrolled diabetes, with, for example, severe hyperglycaemia (high blood glucose), nausea, vomiting, diarrhoea, rapid weight loss, lactic acidosis (see &lsquo;Risk of lactic acidosis&rsquo; below) or ketoacidosis. Ketoacidosis is a condition in which substances called &lsquo;ketone bodies&rsquo; accumulate in the blood and which can lead to diabetic pre-coma. Symptoms include stomach pain, fast and deep breathing, sleepiness or your breath developing an unusual, fruity smell.</p><p>you have lost too much water from your body (dehydration). Dehydration may lead to kidney problems, which can put you at risk for lactic acidosis (see &lsquo;Warnings and precautions&rsquo;).</p><p>you have a severe infection, such as an infection affecting your lung or bronchial system or your kidney. Severe infections may lead to kidney problems, which can put you at risk for lactic acidosis (see &lsquo;Warnings and precautions&rsquo;).</p><p>you have been treated for acute heart problems or have recently had a heart attack or have severe circulatory problems or breathing difficulties. This may lead to a lack in oxygen supply to tissue which can put you at risk for lactic acidosis (see &lsquo;Warnings and precautions&rsquo;).</p><p>you are a heavy drinker of alcohol.</p><p>you are under 18 years of age.</p><p>Warnings and precautions</p><p>Risk of lactic acidosis</p><p><strong>Diaphage<sup>&reg;</sup></strong> SR may cause a very rare, but very serious side effect called lactic acidosis, particularly if your kidneys are not working properly. The risk of developing lactic acidosis is also increased with uncontrolled diabetes, serious infections, prolonged fasting or alcohol intake, dehydration (see further information below), liver problems and any medical conditions in which a part of the body has a reduced supply of oxygen (such as acute severe heart disease).</p><p>If any of the above apply to you, talk to your doctor for further instructions.</p><p>Stop taking <strong>Diaphage<sup>&reg;</sup></strong> SR for a short time if you have a condition that may be associated with dehydration (significant loss of body fluids) such as severe vomiting, diarrhoea, fever, exposure to heat or if you drink less fluid than normal. Talk to your doctor for further instructions.</p><p>Stop taking <strong>Diaphage<sup>&reg;</sup></strong> SR and contact a doctor or the nearest hospital immediately if you experience some of the symptoms of lactic acidosis, as this condition may lead to coma.</p><p>Symptoms of lactic acidosis include:</p><p>vomiting</p><p>stomach ache (abdominal pain)</p><p>muscle cramps</p><p>a general feeling of not being well with severe tiredness</p><p>difficulty in breathing</p><p>reduced body temperature and heartbeat</p><p>Lactic acidosis is a medical emergency and must be treated in a hospital.</p><p>If you need to have major surgery, you must stop taking <strong>Diaphage<sup>&reg;</sup></strong> SR during and for some time after the procedure. Your doctor will decide when you must stop and when to restart your treatment with <strong>Diaphage<sup>&reg;</sup></strong> SR.</p><p>During treatment with <strong>Diaphage<sup>&reg;</sup></strong> SR, your doctor will check your kidney function at least once a year or more frequently if you are elderly and/or if you have worsening kidney function.</p><p>If you are older than 75 years, treatment with <strong>Diaphage<sup>&reg;</sup></strong> SR should not be started to lower the risk of developing type 2 diabetes.</p><p>You may see some remains of the tablets in your stools. Do not worry - this is normal for this type of tablet.</p><p>&nbsp;You should continue to follow any dietary advice that your doctor has given you and you should make sure that you eat carbohydrates regularly throughout the day.</p><p>Do not stop taking this medicine without speaking to your doctor.</p><p>Other medicines and <strong>Diaphage<sup>&reg;</sup></strong> SR</p><p>&nbsp;If you need to have an injection of a contrast medium that contains iodine into your bloodstream, in the context of an X-ray or scan, you must stop taking <strong>Diaphage<sup>&reg;</sup></strong> SR before or at the time of injection. Your doctor will decide when you must stop and when to restart your treatment with <strong>Diaphage<sup>&reg;</sup></strong> SR.</p><p>Tell your doctor if you are taking, have recently taken or might take any other medicines. You may need more frequent blood glucose and kidney function tests, or your doctor may need to adjust the dosage of <strong>Diaphage<sup>&reg;</sup></strong> SR. It is especially important to mention the following:</p><p>Medicines which increase urine production (diuretics (water tablets) such as furosemide).</p><p>Medicines used to treat pain and inflammation (NSAID and COX-2 inhibitors, such as ibuprofen and celecoxib)</p><p>Certain medicines for the treatment of high blood pressure (ACE inhibitors and angiotensin II receptor antagonists)</p><p>Steroids such as prednisolone, mometasone, beclometasone.</p><p>Sympathomimetic medicines including epinephrine and dopamine used to treat heart attacks and low blood pressure. Epinephrine is also included in some dental anaesthetics.</p><p>Medicines that may change the amount of <strong>Diaphage<sup>&reg;</sup></strong> SR in your blood, especially if you have reduced kidney function (such as verapamil, rifampicin, cimetidine, dolutegravir, ranolazine, trimethoprim, vandetanib, isavuconazole, crizotinib, olaparib).</p><p>Diaphage<strong><sup>&reg;</sup></strong> SR with alcohol:</p><p>Avoid excessive alcohol intake while taking <strong>Diaphage<sup>&reg;</sup></strong> SR since this may increase the risk of lactic acidosis (see section &lsquo;Warnings and precautions&rsquo;).</p><p>Pregnancy and breast-feeding</p><p>&nbsp;Do not take <strong>Diaphage<sup>&reg;</sup></strong> SR if you are pregnant or breast feeding. Ask your doctor or pharmacist for advice before taking any medicine.</p><p>Driving and using machines</p><p>&nbsp;<strong>Diaphage<sup>&reg;</sup></strong> SR taken on its own does not cause &lsquo;hypos&rsquo; (symptoms of low blood sugar or hypoglycaemia, such as faintness, confusion and increased sweating) and therefore should not affect your ability to drive or use machinery.</p><p>You should be aware, however, that <strong>Diaphage<sup>&reg;</sup></strong> SR taken with other antidiabetic medicines can cause hypos, so in this case you should take extra care when driving or operating machinery.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Your doctor may prescribe <strong>Diaphage<sup>&reg;</sup></strong> SR for you to take on its own, or in combination with other oral antidiabetic medicines or insulin.</p><p>Always take <strong>Diaphage<sup>&reg;</sup></strong> SR exactly as your doctor has told you.</p><p>You should check with your doctor or pharmacist if you are not sure.</p><p>Swallow the tablets whole with a glass of water, do not chew.</p><p>Recommended dose</p><p>&nbsp;Usually you will start treatment with 500 milligrams <strong>Diaphage<sup>&reg;</sup></strong> SR daily. After you have been taking <strong>Diaphage<sup>&reg;</sup></strong> SR for about 2 weeks, your doctor may measure your blood sugar and adjust the dose. The maximum daily dose is 2000 milligrams of <strong>Diaphage<sup>&reg;</sup></strong> SR. If you have reduced kidney function, your doctor may prescribe a lower dose.</p><p>Normally, you should take the tablets once a day, with your evening meal.</p><p>In some cases, your doctor may recommend that you take the tablets twice a day. Always take the tablets with food.</p><p>If you take more <strong>Diaphage<sup>&reg;</sup></strong> SR than you should If you take extra tablets by mistake you need not worry, but if you have unusual symptoms, contact your doctor. If the overdose is large, lactic acidosis is more likely. Symptoms of lactic acidosis are non-specific, such as vomiting, bellyache with muscle cramps, a general feeling of not being well with severe tiredness, and difficulty in breathing. Further symptoms are reduced body temperature and heartbeat. If you experience some of these symptoms, you should immediately seek medical attention, as lactic acidosis may lead to coma. Stop taking <strong>Diaphage<sup>&reg;</sup></strong> SR immediately and contact a doctor or the nearest hospital straightaway.</p><p>&nbsp;If you forget to take <strong>Diaphage<sup>&reg;</sup></strong> SR</p><p>&nbsp;Take it as soon as you remember with some food. Do not take a double dose to make up for a forgotten dose.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, <strong>Diaphage<sup>&reg;</sup></strong> SR can cause side effects, although not everybody gets them. The following side effects may occur:</p><p><strong>Diaphage<sup>&reg;</sup></strong> SR may cause a very rare (may affect up to 1 user in 10,000) but very serious side effect called lactic acidosis (see section &lsquo;Warnings and Precautions&rsquo;). If this happens, you must stop taking <strong>Diaphage<sup>&reg;</sup></strong> SR and contact a doctor or the nearest hospital immediately, as lactic acidosis may lead to coma.</p><p><strong>Diaphage<sup>&reg;</sup></strong> SR may cause abnormal liver function tests and hepatitis (inflammation of the liver) which may result in jaundice (may affect up to 1 user in 10,000). If you develop yellowing of the eyes and/or skin contact your doctor immediately.</p><p>&nbsp;Other possible side effects are listed by frequency as follows:</p><p>Very common (affects more than 1 person in 10):</p><p>Diarrhoea, nausea, vomiting, stomach ache or loss of appetite. If you get these, do not stop taking the tablets as these symptoms will normally go away in about 2 weeks. It helps if you take the tablets with or immediately after a meal.</p><p>Common (affects less than 1 person in 10, but more than 1&nbsp;person in 100):</p><p>Taste disturbances</p><p>Very rare (affects less than 1 person in 10,000):</p><p>Decreased vitamin B12 levels</p><p>Skin rashes including redness, itching and hives.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep <strong>Diaphage<sup>&reg;</sup></strong> SR tablets out of the sight and reach of children.</p><p>Do not use them after the expiry date that is printed on the pack after &ldquo;EXP&rdquo;. The expiry date refers to the last day of that month.</p><p>Do not store above 30&deg;C.</p><p>Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. These measures will help to protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Each extended release tablet contains Metformin Hydrochloride 1000mg in packs of 28 tablets.</p><p>Hospital packs are also available.</p><p>The other ingredients are Carboxy Methyl Cellulose Na, Hydroxypropyl Mehyl E5 , Hydroxypropyl Mehyl KI00 , Cellulose &amp; Magnesium Stearate.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                White to off-white oblong tablet embossed with “D05” on one side and plain on the other.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The United Pharmaceutical Mfg. Co. Ltd.</p><p>P.O. Box 69, Amman 11591-Jordan</p><p>Tel:&nbsp; + 962 (6) 416 2901</p><p>Fax: + 962 (6) 416 2905</p><p>E-mail: upm_info@mspharma.com&nbsp; United Pharmaceutical Mfg. Co. Ltd.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Sep-19
 M3-14-0617

            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p>&nbsp;تحتوي أقراص ديافاج طويلة المفعول على المادة الفعالة ميتفورمين هيدروكلورايد وتنتمي إلى مجموعة من الأدوية تسمى بيجوانيدز، والتي تستخدم في علاج النوع الثاني من مرض السكر (الذي لا يعتمد على الإنسولين حصرًا). يستخدم دواء ديافاج بالمشاركة مع الحمية الغذائية المناسبة وممارسة الرياضة من أجل خفض خطر الإصابة بمرض السكر النوع الثاني، وذلك إذا كانت الحمية الغذائية المناسبة وممارسة الرياضة لمدة 3 إلى 6 أشهر غير كافية للتحكم في أن يظل مستوى السكر في الدم طبيعيا.&nbsp; أنت أكثر عرضة للإصابة بمرض السكري من النوع الثاني إذا كنت تعاني من حالات مرضية إضافية مثل ارتفاع ضغط الدم ، أو تبلغ من العمر أكثر من 40 عامًا ، أو تعاني من وجود كمية غير طبيعية من الدهون في الدم أو لديكِ تاريخ مرضي للإصابة بالسكري أثناء الحمل.</p><p>&nbsp;هذا الدواء فعال خاصة إذا كان عمرك أقل من 45 عامًا، أو كنت تعاني من زيادة كبيرة في الوزن، أو كان لديك ارتفاع في مستويات السكر في الدم بعد تناول الطعام أو أنك قد عانيت من مرض السكر أثناء الحمل.</p><p>&nbsp;يستخدم دواء ديافاج في علاج مرض السكر من النوع الثاني عندما لا تكون التغييرات في الحمية الغذائية وممارسة الرياضة وحدها كافية للتحكم في نسبة الجلوكوز في الدم (السكر). الأنسولين هو هرمون يمكّن أنسجة الجسم من الحصول على الجلوكوز من الدم واستخدامه في انتاج الطاقة أو للتخزين من أجل الاستخدام في المستقبل. المرضى الذين يعانون مرض السكر من النوع الثاني لا يصنعون كمية كافية من الأنسولين في البنكرياس أو أن أجسامهم لا تستجيب بشكل صحيح للإنسولين الذي تصنعه. يتسبب ذلك في تراكم الجلوكوز في الدم مما قد يؤدي إلى عدد من المشاكل الخطيرة طويلة الأجل، لذلك من المهم أن تستمر في تناول الدواء، على الرغم من أنك قد لا تعاني من أية أعراض واضحة.</p><p>&nbsp;يعمل دواء ديافاج على زيادة حساسية الجسم للإنسولين والمساعدة في استرجاع الطريقة الطبيعية التي يستخدم&nbsp; فيها الجسم الجلوكوز.&nbsp; دواء ديافاج له علاقة إما بالمحافظة على وزن الجسم ثابتا أو بفقدان قليل في الوزن.</p><p>&nbsp;صُنعت&nbsp; أقراص ديافاج طويلة المفعول خصيصا من أجل أن يتم إفراز الدواء بصورة بطيئة في الجسم، وبالتالي فإن هذا الدواء يختلف عن كثير من الأدوية الأخرى التي تحتوي على الميتفورمين.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p><strong>لا تتناول ديافاج طويل المفعول في الحالات التالية:</strong></p><p>&nbsp;إذا كان لديك حساسية مفرطة لمادة الميتفورمين أو لأي مكونات أخرى في هذا الدواء (من المكونات المذكورة في الفقرة 6). قد يتسبب رد الفعل التحسسي في الإصابة بالطفح الجلدي أو الشعور بالحك أو قصر النفس.</p><p>&nbsp;إذا كنت تعاني من مشاكل في الكبد</p><p>إذا كنت تعاني من نقص شديد في وظائف الكلية</p><p>إذا كنت تعاني من عدم انتظام في مستوى السكر في الدم، وتصاحبه أعراض؛ على سبيل المثال: ارتفاع شديد لمستوى السكر في الدم، الغثيان، القيء، الإسهال، الفقدان السريع للوزن، حموضة الدم باللاكتيك&nbsp; (حمض اللاكتيك) (يرجى الاطلاع على الفقرة أدناه &ldquo;مخاطر حمض اللاكتيك&rdquo;) أو الحمض الكيتوني. الحمض الكيتوني هي حالة تتراكم فيها مادة تسمى الأجسام الكيتونية في الدم مما قد يؤدي إلى مرحلة ما قبل الغيبوبة السكرية. وتشمل أعراضه وجود ألم في المعدة أو التنفس بسرعة وبعمق أو الأرق أو تغير في رائحة النفس، رائحة الفواكه.</p><p>&nbsp;إذا كان جسمك قد فقد كمية كبيرة من الماء (جفاف). قد يؤدي الجفاف إلى الإصابة بمشاكل في الكلية، والتي قد تضعك في خطورة الإصابة حمض اللاكتيك (يرجى الاطلاع على فقرة التحذيرات والاحتياطات).</p><p>&nbsp;إذا كنت تعاني من عدوى شديدة مثل العدوى التي تصيب الرئة أو الشعب الهوائية أو الكلية. قد تؤدي العدوي الشديدة إلى الإصابة بمشاكل في الكلية، والتي قد تضعك في خطورة الإصابة حمض اللاكتيك (يرجى الاطلاع على فقرة التحذيرات والاحتياطات).</p><p>&nbsp;إذا كنت قد عولجت من مشاكل قلبية حادة أو تعرضت مؤخراً لأزمة قلبية أو لديك مشاكل في الدورة الدموية أو صعوبات في التنفس. قد يؤدي ذلك إلى نقص في وصول الأكسجين إلى الأنسجة مما قد يضعك في خطورة الإصابة حمض اللاكتيك (يرجى الاطلاع على فقرة التحذيرات والاحتياطات).</p><p>&nbsp;إذا كنت تدخن أو تشرب الكحوليات بشراهة.</p><p>&nbsp;إذا كنت أصغر من 18 عاما.</p><p>&nbsp;التحذيرات والاحتياطات</p><p>&nbsp;خطورة الإصابة بحمض اللاكتيك</p><p>&nbsp;قد يتسب هذا الدواء في حدوث آثار جانبية نادرة جدًا ولكنها خطيرة جدًا تسمى حمض اللاكتيك، خاصة إذا كانت الكلية لا تعمل بشكل صحيح. يزداد خطر الإصابة بحمض اللاكتيك أيضًا بسبب مرض السكري غير المنضبط أو العدوى الخطيرة أو الصيام الطويل أو تناول الكحوليات أو الجفاف (توجد مزيد من المعلومات أدناه)، أو وجود مشاكل في الكبد بالإضافة لأي حالة طبية يعاني فيها جزء من الجسم من نقص في وصول الأوكسجين ( مثل مرض القلب الحاد الشديد).</p><p>&nbsp; إذا كنت تعاني من أي مما سبق ذكره بالأعلى؛ فيجب استشارة الطبيب من أجل مزيد من الارشادات.</p><p>&nbsp;توقف عن تناول دواء ديافاج لفترة قصيرة إذا كانت لديك حالة قد يصاحبها الإصابة بالجفاف (فقدان كبير لسوائل الجسم) مثل القيء الشديد والإسهال والحمى والتعرض للحرارة أو إذا كنت تشرب كمية أقل من السوائل عن المعتاد. استشر الطبيب من أجل مزيد من الارشادات.</p><p>&nbsp;توقف عن تناول الدواء واستشر الطبيب فورا أو توجه في الحال إلى أقرب مستشفى إذا عانيت من أية أعراض لحمض اللاكتيك لأن هذه الحالة قد تؤدي إلى الغيبوبة.&nbsp;</p><p>&nbsp;تشمل أعراض حمض اللاكتيك على التالي:</p><p>&nbsp;القيء</p><p>&nbsp;ألم في المعدة (ألم في البطن)</p><p>&nbsp;تقلصات في العضلات</p><p>&nbsp;شعور عام بالمرض مع إرهاق شديد</p><p>&nbsp;صعوبة التنفس</p><p>&nbsp;انخفاض حرارة الجسم وبطء سرعة ضربات القلب</p><p>&nbsp;يعد حمض اللاكتيك حالة طارئة ويجب علاجها داخل المستشفى.</p><p>&nbsp;إذا كنت بحاجة إلى إجراء عملية جراحية كبيرة، فيجب أن تتوقف عن تناول دواء ديافاج لبعض الوقت أثناء وبعد العملية. سيقرر الطبيب متى يجب عليك أن تتوقف عن تناول الدواء ومتى تعود لتناوله مرة أخرى.</p><p>&nbsp;سيفحص الطبيب حالة وظائف الكلية أثناء تناولك هذا الدواء على الأقل مرة كل عام أو أكثر من ذلك في حالة المرضى كبار السن و / أو إذا كنت تعاني من تدهور في وظائف الكلية.</p><p>&nbsp;إذا كنت تبلغ من العمر أكثر من 75 عاما، فيجب عدم تناول هذا الدواء من أجل تقليل مخاطر الإصابة بمرض السكر من النوع الثاني.</p><p>&nbsp;قد ترى بعض الأجزاء المتبقية من أقراص الدواء في البراز. لا تقلق - فإن ذلك يعد طبيعيا في هذا النوع من الأقراص.</p><p>&nbsp;يجب أن تستمر في متابعة كل النصائح الغذائية التي قدمها لك الطبيب، وعليك التأكد من تناول الكربوهيدرات بانتظام على مدار اليوم.</p><p>&nbsp;لا تتوقف عن تناول هذا الدواء إلا بعد مناقشة ذلك مع الطبيب.</p><p>&nbsp;تناول أدوية أخرى مع دواء ديافاج طويل المفعول</p><p>&nbsp;إذا كنت بحاجة إلى حقن صبغة تحتوي على اليود في الدم، من أجل إجراء فحص بالأشعة السينية أو المسح الإشعاعي، فيجب عليك التوقف عن تناول ديافاج قبل أو في وقت الحقن. سيقرر الطبيب متى يجب عليك أن تتوقف عن تناول الدواء ومتى تعود لتناوله مرة أخرى.</p><p>&nbsp;يجب إخبار الطبيب إذا كنت تتناول أدوية أو تناولت مؤخرًا بعض الأدوية أو تنوي تناول أي دواء آخر. قد تحتاج لإجراء فحوصات متكررة لمستوى السكر في الدم وفحوصات وظائف الكلية، أو قد يحتاج الطبيب لإجراء تعديلات على جرعتك من الدواء. يجب إبلاغ الطبيب فيما يتعلق بتناول الأدوية التالية:</p><p>الأدوية التي تزيد كمية الانتاج البولي (الأدوية المدرة للماء) مثل دواء فروسيمايد.</p><p>&nbsp;الأدوية التي تستخدم في علاج الألم والالتهابات (NSAID&nbsp; ومثبطات إنزيم كوكس-2 مثل دواء إيبيبروفين وسيليكوكسيب).</p><p>&nbsp;بعض الأدوية التي تستخدم في علاج ارتفاع ضغط الدم (الأدوية المثبطة للإنزيم المُحوّل للأنجيوتنسين وحاصرات مستقبلات الأنجيوتنسين 2).</p><p>&nbsp;الاستيرويدات مثل دواء بريدنيزولون وموميتازون وبيكلوميتازون.</p><p>الأدوية المحاكية للعصب السمبثاوي بما في ذلك دواء إيبينيفرين ودوبامين التي تستخدم في علاج النوبات القلبية وانخفاض ضغط الدم. يستخدم دواء إيبينيفرين أيضا في بعض حالات التخدير في عمليات الأسنان.</p><p>&nbsp;الأدوية التي تغير من مستوى دواء ديافاج في الدم خاصة إذا كنت تعاني من نقص في وظائف الكلية (مثل دواء فيراباميل ودريفامبسين وسيمتدين ودوليتيجرافير وريميثوبريم وفانديتانيب وايسافوكونازول وكريزوتينب وأولاباريب).</p><p><strong>&nbsp;تناول دواء ديافاج&nbsp; مع المشروبات الكحولية:</strong></p><p>&nbsp;تجنب التناول المفرط للمشروبات الكحولية أثناء تناولك هذا الدواء حيث أن ذلك قد يزيد من مخاطر إصابتك حمض اللاكتيك (يرجى الاطلاع على فقرة التحذيرات والاحتياطات).</p><p>&nbsp;الحمل والرضاعة الطبيعية</p><p>يجب تجنب تناول هذا الدواء في حالات السيدات الحوامل أو اللاتي تقمن بالرضاعة الطبيعية. يجب استشارة الطبيب أو الصيدلي قبل تناول أي دواء.</p><p>&nbsp;القيادة واستخدام الآلات</p><p>&nbsp;لا يتسبب تناول دواء ديافاج&nbsp; بمفرده بالإصابة بأعراض نقص مستوى السكر في الدم (مثل الإغماء وتشوش الذهن وزيادة التعرق) وبناء على ذلك فإنه لا يؤثر على قدرتك في القيادة واستخدام الآلات.</p><p>&nbsp;ومع ذلك ، يجب أن تكون على دراية بأن ديافاج الذي تم تناوله مع أدوية أخرى مضادة لمرض السكر يمكن أن يسبب نقصًا في&nbsp; مستوى السكر في الدم، لذلك في هذه الحالة يجب منح مزيد من التحوّط عند القيادة أو تشغيل الآلات.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>قد يصف لك الطبيب هذا الدواء لتأخذه بمفرده أو برفقة بعض الأدوية الأخرى المضادة لمرض السكر أو مع الإنسولين.</p><p>&nbsp;يجب عليك تناول هذا الدواء وفقًا لتعليمات الطبيب.</p><p>&nbsp;يرجى التوجه بالسؤال للطبيب أو الصيدلي في حالة عدم تأكدك.</p><p>&nbsp;قم ببلع القرص بأكمله باستخدام كوب من الماء، ولا تقم بمضغه.</p><p>&nbsp;الجرعة الموصى بها</p><p>&nbsp;عادة ما ستبدأ العلاج بجرعة 500 ملغم يوميا.&nbsp; قد يحتاج الطبيب إلى قياس مستوى السكر في الدم وتعديل جرعة الدواء بعد تناولك له لمدة أسبوعين تقريبا.&nbsp; أقصى جرعة يمكن تناولها في اليوم هي 2000 ملغم من هذا الدواء. قد يصف الطبيب جرعة أقل إذا كنت تعاني من نقص في وظائف الكلية.</p><p>&nbsp;وفي الطبيعي فيجب أن تتناول الأقراص مرة واحدة في اليوم مع وجبة الطعام المسائية.</p><p>&nbsp;وفي بعض الحالات؛ قد ينصح الطبيب بتناول قرصين من الدواء في اليوم الواحد. تناول الدواء دوما مع الطعام.</p><p>&nbsp;إذا تناولت جرعة من الدواء أكثر من الموصى بها أو إذا تناولت جرعات إضافية بالخطأ، فلا داعي للقلق، لكن استشر الطبيب إذا عانيت من أية أعراض غير طبيعية.&nbsp; إذا كانت الجرعة الزائد كبيرة جدا فمن المرجح أن تصاب حمض اللاكتيك. أعراض حمض اللاكتيك غير محددة؛ مثل القيء وألم البطن مع تقلصات في العضلات وشعور عام بالمرض مع إرهاق شديد وصعوبة في التنفس. والأعراض الاضافية تشمل انخفاض حرارة الجسم وبطء سرعة ضربات القلب. إذا عانيت من أي من هذه الأعراض، فينبغي عليك طلب الرعاية الطبية لأن حمض اللاكتيك قد يتسبب في حدوث غيبوبة. توقف عن تناول الدواء على الفور واستشر الطبيب أو توجه في الحال لأقرب مستشفى إليك.</p><p>&nbsp;إذا نسيت تناول الدواء</p><p>&nbsp;تناول الدواء في أقرب وقت تتذكر فيه، على أن تتناوله مع الطعام. لا تتناول جرعة مزدوجة لتعويض جرعتك الفائتة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p>مثل كافة الأدوية، فإن هذا الدواء يمكن أن يتسبب في ظهور بعض الأعراض جانبية، وعلى الرغم من ذلك فإنها لا تظهر على جميع المرضى. قد تحدث هذه الأعراض الجانبية الآتية:</p><p>&nbsp;قد يتسبب دواء ديافاج في عرض جانبي نادر جدا (قد يصيب 1 من بين 10.000 شخص) ولكنه خطير جدا؛ ويسمى ذلك حمض اللاكتيك (يرجى الاطلاع على فقرة التحذيرات والاحتياطات). إذا حدث ذلك؛ فيجب أن تتوقف عن تناول الدواء واستشر الطبيب أو توجه في الحال لأقرب مشفى إليك، لأن حمض اللاكتيك قد يتسبب في حدوث غيبوبة.</p><p>&nbsp;قد يتسبب دواء ديافاج في اختلال فحوصات وظائف الكبد مع التهاب في الكبد والذي قد ينتج عنه يرقان (قد يصيب 1 من بين 10.000 شخص). إذا عانيت من اصفرار في العين و / أو الجلد، استشر الطبيب على الفور.</p><p>&nbsp;هاك قائمة بالأعراض الجانبية المحتملة الأخرى بناء على نسب تكررها:</p><p>&nbsp;الأعراض الجانبية المألوفة جدا ( قد تؤثر في أكثر من 1 من بين 10 أشخاص):</p><p>&nbsp;الغثيان والقيء والإسهال وألم في المعدة أو فقدان الشهية. إذا عانيت من أي من هذه الأعراض، فلا تتوقف عن تناول الدواء لأن هذه الأعراض عادة ما تختفي في خلال أسبوعين. سيساعد في ذلك إن تناولت الدواء مع الطعام أو بعد تناوله مباشرة.</p><p>&nbsp;الأعراض الجانبية المألوفة (تؤثر في أقل من 1 من بين 01 أشخاص، ولكنها تؤثر في أكثر من 1 من بين 001 شخص):</p><p>&nbsp;اختلال في حاسة التذوق</p><p>الأعراض الجانبية النادرة جدا (تؤثر في أقل من 1 من بين 10,000 شخص):</p><p>&nbsp;نقص مستويات فيتامين ب 21</p><p>&nbsp;طفح جلدي بما في ذلك احمرار الجلد وشعور بالحكة والشرى.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>- يُحفظ الدواء بعيدا عن الأيدي وعن متناول الأطفال.</p><p>- لا تستخدم الدواء بعد مرور تاريخ انتهاء الصلاحية الموضح على العبوة بعد كلمة EXP. يشير تاريخ انتهاء الصلاحية إلى اليوم الأخير في الشهر.</p><p>- يحفظ في درجة حرارة لاتتجاوز 30 درجة مئوية.</p><p>- لا تقم بإلقاء أي أدوية في مياه الصرف أو في النفايات المنزلية. وبدلاً عن ذلك قم باستشارة الصيدلي عن كيفية التخلص الآمن من الأدوية التي لم تعد بحاجة إليها. ستساعد هذه الإجراءات في المحافظة على البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p><strong>محتويات أقراص دواء ديافاج</strong><strong> </strong></p><p>يحتوي كل قرص طويل المفعول على 1000 ملغم من مادة ميتفورمين هيدروكلورايد في عبوات بها 28 قرص.</p><p><em>&nbsp;تتوفر أيضا عبوات خاصة بالمستشفيات.</em></p><p>&nbsp;باقي المكونات: كربوكسي ميثيل سيليولوز الصوديوم، هيدروكسي بروبيل ميثيل E5 ، هيدروكسي بروبيل ميثيل KI00 ، سيليلوز و ماغنسيوم استيارات.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p>قرص مستطيل لونه أبيض منقوش عليه &laquo;D05&rdquo; على جانب ومنبسط على الجانب الآخر.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p>إم إس فارما &ndash; الأردن</p><p>الشركة المتحدة لصناعة الأدوية ذ.م.م</p><p>ص.ب. 69، عمان 11591- الأردن</p><p>هاتف: + 962 (6) 416 2901</p><p>فاكس: + 962 (6) 416 2905</p><p>البريد الإلكترونيupm_info@mspharma.com</p><p>صنعت بواسطة:</p><p>المتحدة للصناعات الدوائية</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            تمت مراجعة هذه النشرة في: بتاريخ  سبتمبر, 2019؛ 
رقم النسخة : M3-14-0617
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                DIAPHAGE® 1gm SR Tablets
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Material Name
Function
Amount (mg)/ one tablet
Metformin HCL
Active Material
1000
Carboxy Methyl Cellulose Na
Binder
65.0
Hydroxypropyl Methyl Cellulose (Methocel E5)
Binder
80.5
Hydroxypropyl Methyl Cellulose (Methocel K1000)
Hydro gel polymer for controlled release matrix
290.0
Magnesium Stearate
Lubricant
14.5
Total
1450
For a full list of excipients, see section 6.1
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Film Coated Tablets
DIAPHAGE® 1gm F/C Tablets: White to off-white oblong tablet embossed with "D05" on one side and plain on the other.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>&bull; Reduction in the risk or delay of the onset of type 2 diabetes mellitus in adult, overweight patients with IGT* and/or IFG*, and/or increased HbA1C who are:<br />- At high risk for developing overt type 2 diabetes mellitus.<br />- Still progressing towards type 2 diabetes mellitus despite implementation of intensive lifestyle change for 3 to 6 months.<br />Treatment with DIAPHAGE&reg; SR must be based on a risk score incorporating appropriate measures of glycemic control and including evidence of high cardiovascular risk.<br />Lifestyle modifications should be continued when metformin is initiated, unless the patient is unable to do so because of medical reasons.<br />*IGT: Impaired Glucose Tolerance; IFG: Impaired Fasting Glucose<br />&bull; Treatment of type 2 diabetes mellitus in adults, particularly in overweight patients, when dietary management and exercise alone does not result in adequate glycemic control.</p><p>DIAPHAGE&reg; SR may be used as monotherapy or in combination with other oral antidiabetic agents, or with insulin.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Posology</strong><br />Adults with normal renal function (GFR &ge; 90 mL/min)<br />Reduction in the risk or delay of the onset of type 2 diabetes<br />&bull; Metformin should only be considered where intensive lifestyle modifications for 3 to 6 months have not resulted in adequate glycemic control.<br />&bull; The therapy should be initiated with one tablet metformin SR 500mg once daily with the evening meal.<br />&bull; After 10 to 15 days dose adjustment on the basis of blood glucose measurements is recommended (OGTT and/or FPG and/or HbA1C values to be within the normal range). A slow increase of dose may improve gastro-intestinal tolerability.<br />The maximum recommended dose is 2 tablets (2000 mg) once daily with the evening meal.<br />&bull; It is recommended to regularly monitor (every 3-6 months) the glycemic status (OGTT and/or FPG and/or HbA1c value) as well as the risk factors to evaluate whether treatment needs to be continued, modified or discontinued.<br />&bull; A decision to re-evaluate therapy is also required if the patient subsequently implements improvements to diet and/or exercise, or if changes to the medical condition will allow increased lifestyle interventions to be possible.<br />Monotherapy in Type 2 diabetes mellitus and combination with other oral antidiabetic agents:<br />&bull; The usual starting dose is one tablet of metformin SR 500mg once daily.<br />&bull; After 10 to 15 days the dose should be adjusted on the basis of blood glucose measurements. A slow increase of dose may improve gastro-intestinal tolerability. The maximum recommended dose is 4 tablets daily.<br />&bull; Dosage increases should be made in increments of 500mg every 10-15 days, up to a maximum of 2000mg once daily with the evening meal. If glycemic control is not achieved on DIAPHAGE&reg; SR 1000mg twice daily should be considered, with both doses being given with food. If glycemic control is still not achieved, patients may be switched to standard metformin tablets to a maximum dose of 3000 mg daily.<br />&bull; In patients already treated with metformin tablets, the starting dose of DIAPHAGE&reg; SR should be equivalent to the daily dose of metformin immediate release tablets. In patients treated with metformin at a dose above 2000 mg daily, switching to DIAPHAGE&reg; SR is not recommended.<br />&bull; If transfer from another oral antidiabetic agent is intended: discontinue the other agent and initiate DIAPHAGE&reg; SR at the dose indicated above.<br />&bull; DIAPHAGE&reg; SR 1000 mg are intended for patients who are already treated with metformin tablets (prolonged or immediate release).<br />&bull; The dose of DIAPHAGE&reg; SR 1000 mg should be equivalent to the daily dose of metformin tablets (prolonged or immediate release), up to a maximum dose of 2000 mg respectively, given with the evening meal.<br />Combination with insulin<br />Metformin and insulin may be used in combination therapy to achieve better blood glucose control. The usual starting dose of DIAPHAGE&reg; is one 500 mg tablet once daily, while insulin dosage is adjusted on the basis of blood glucose measurements.<br />For patients already treated with metformin and insulin in combination therapy, the dose of DIAPHAGE&reg; SR 1000 mg should be equivalent to the daily dose of metformin tablets up to a maximum of 2000 mg respectively, given with the evening meal, while insulin dosage is adjusted on the basis of blood glucose measurements.<br />Elderly<br />Due to the potential for decreased renal function in elderly subjects, the metformin dosage should be adjusted based on renal function. Regular assessment of renal function is necessary.<br />Benefit in the reduction of risk or delay of the onset of type 2 diabetes mellitus has not been established in patients 75 years and older and metformin initiation is therefore not recommended in these patients.<br />Renal impairment<br />A GFR should be assessed before initiation of treatment with metformin containing products and at least annually thereafter. In patients at an increased risk of further progression of renal impairment and in the elderly, renal function should be assessed more frequently, e.g. every 3-6 months.<br />GFR (mL/min)&nbsp; &nbsp; &nbsp;Total maximum daily dose&nbsp; &nbsp; Additional considerations<br />60-89 &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; 2000 mg&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; Dose reduction may be considered in relation to declining renal function.<br />45-59&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;2000 mg&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&nbsp;Factors that may increase the risk of lactic acidosis should be reviewed before considering initiation of metformin.</p><p>30-44 &nbsp; &nbsp; &nbsp;&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; 1000 mg&nbsp;&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; The starting dose is at most half of the maximum dose.<br />&lt;30&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&nbsp; &nbsp;-&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; Metformin is contraindicated.</p><p><br />Paediatric population<br />In the absence of available data, Glucophage SR should not be used in children.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                - Hypersensitivity to metformin or to any of the excipients listed in section 6.1.
- Any type of acute metabolic acidosis (such as lactic acidosis, diabetic ketoacidosis)
- Diabetic pre-coma
- Severe renal failure (GFR < 30 mL/min).
- Acute conditions with the potential to alter renal function such as:
• dehydration,
• severe infection,
• shock
- Disease which may cause tissue hypoxia (especially acute disease, or worsening of chronic disease) such as:
• decompensated heart failure,
• respiratory failure,
• recent myocardial infarction,
• shock
- Hepatic insufficiency, acute alcohol intoxication, alcoholism
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>- Lactic acidosis<br />Lactic acidosis, a very rare, but serious, metabolic complication, most often occurs at acute worsening of renal function or cardiorespiratory illness or sepsis. Metformin accumulation occurs at acute worsening of renal function and increases the risk of lactic acidosis.<br />In case of dehydration (severe diarrhoea or vomiting, fever or reduced fluid intake), metformin should be temporarily discontinued and contact with a health care professional is recommended.<br />Medicinal products that can acutely impair renal function (such as antihypertensives, diuretics and NSAIDs) should be initiated with caution in metformin-treated patients. Other risk factors for lactic acidosis are excessive alcohol intake, hepatic insufficiency, inadequately controlled diabetes, ketosis, prolonged fasting and any conditions associated with hypoxia, as well as concomitant use of medicinal products that may cause lactic acidosis.<br />Patients and/or care-givers should be informed of the risk of lactic acidosis. Lactic acidosis is characterised by acidotic dyspnoea, abdominal pain, muscle cramps, asthenia and hypothermia followed by coma. In case of suspected symptoms, the patient should stop taking metformin and seek immediate medical attention. Diagnostic laboratory findings are decreased blood pH (&lt;7.35), increased plasma lactate levels (&gt;5 mmol/L) and an increased anion gap an lactate/pyruvate ratio.<br />- Renal function<br />GFR should be assessed before treatment initiation and regularly thereafter, see section 4.2. Metformin is contraindicated in patients with GFR&lt;30 mL/min and should be temporarily discontinued in the presence of conditions that alter renal function.<br />- Cardiac function<br />Patients with heart failure are more at risk of hypoxia and renal insufficiency. In patients with stable chronic heart failure, metformin may be used with a regular monitoring of cardiac and renal function.<br />For patients with acute and unstable heart failure, metformin is contraindicated (see section 4.3).<br />- Elderly<br />Due to the limited therapeutic efficacy data in the reduction of risk or delay of type 2 diabetes in patients 75 years and older, metformin initiation is not recommended in these patients.<br />- Administration of iodinated contrast agents<br />Intravascular administration of iodinated contrast agents may lead to contrast induced nephropathy, resulting in metformin accumulation and an increased risk of lactic acidosis. Metformin should be discontinued prior to or at the time of the imaging procedure and not restarted until at least 48 hours after, provided that renal function has been reevaluated and found to be stable.<br />- Surgery<br />Metformin must be discontinued at the time of surgery under general, spinal or epidural anaesthesia. Therapy may be restarted no earlier than 48 hours following surgery or resumption of oral nutrition and provided that renal function has been re-evaluated and found to be stable.<br />- Other precautions<br />All patients should continue their diet with a regular distribution of carbohydrate intake during the day. Overweight patients should continue their energy-restricted diet.<br />The usual laboratory tests for diabetes monitoring should be performed regularly.<br />Metformin alone never causes hypoglycaemia, although caution is advised when it is used in combination with insulin or other oral antidiabetics (e.g. sulphonylureas or meglitinides). The tablet shells may be present in the faeces. Patients should be advised that this is normal.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Concomitant use not recommended:<br />Alcohol<br />Alcohol intoxication is associated with an increased risk of lactic acidosis, particularly in case of fasting, malnutrition or hepatic impairment.<br />Iodinated contrast agents<br />Metformin must be discontinued prior to or at the time of the imaging procedure and not restarted until at least 48 hours after, provided that renal function has been re-evaluated and found to be stable.<br />Combinations requiring precautions for use<br />Some medicinal products can adversely affect renal function which may increase the risk of lactic acidosis, e.g. NSAIDs, including selective cyclooxygenase (COX) II inhibitors, ACE inhibitors, angiotensin II receptor antagonists and diuretics, especially loop diuretics. When starting or using such products in combination with metformin, close monitoring of renal function is necessary.<br />Medicinal products with intrinsic hyperglycemic activity (e.g. glucocorticoids (systemic and local routes) and sympathomimetics).<br />More frequent blood glucose monitoring may be required, especially at the beginning of treatment. If necessary, adjust the metformin dosage during therapy with the other drug and upon its discontinuation.<br />Organic cation transporters (OCT)<br />Metformin is a substrate of both transporters OCT1 and OCT2.<br />Co-administration of metformin with<br />&bull; Inhibitors of OCT1 (such as verapamil) may reduce efficacy of metformin.<br />&bull; Inducers of OCT1 (such as rifampicin) may increase gastrointestinal absorption and efficacy of metformin.<br />&bull; Inhibitors of OCT2 (such as cimetidine, dolutegravir, ranolazine, trimethoprim, vandetanib, isavuconazole) may decrease the renal elimination of metformin and thus lead to an increase in metformin plasma concentration.<br />&bull; Inhibitors of both OCT1 and OCT2 (such as crizotinib, olaparib) may alter efficacy and renal elimination of metformin.<br />Caution is therefore advised, especially in patients with renal impairment, when these drugs are co-administered with metformin, as metformin plasma concentration may increase. If needed, dose adjustment of metformin may be considered as OCT inhibitors/inducers may alter the efficacy of metformin.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pregnancy<br />Uncontrolled diabetes during pregnancy (gestational or permanent) is associated with increased risk of congenital abnormalities and perinatal mortality.<br />A limited amount of data from the use of metformin in pregnant women does not indicate an increased risk of congenital abnormalities. Animal studies do not indicate harmful effects with respect to pregnancy, embryonic or fetal development, parturition or postnatal development.<br />When the patient plans to become pregnant and during pregnancy, it is recommended that impaired glycemic control or diabetes are not treated with metformin. For diabetes it is recommended that insulin should be used to maintain blood glucose levels as close to normal as possible to reduce the risk of malformations of the foetus.<br />Breast-feeding<br />Metformin is excreted into human breast milk. No adverse effects were observed in breastfed newborns/infants.<br />However, as only limited data are available, breastfeeding is not recommended during metformin treatment. A decision on whether to discontinue breast-feeding should be made, taking into account the benefit of breast-feeding and the potential risk to adverse effect on the child.<br />Fertility<br />Fertility of male or female rats was unaffected by metformin when administered at doses as high as 600 mg/kg/day, which is approximately three times the maximum recommended human daily dose based on body surface area comparisons.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Metformin monotherapy does not cause hypoglycaemia and therefore has no effect on the ability to drive or to use machines.<br />However, patients should be alerted to the risk of hypoglycaemia when metformin is used in combination with other antidiabetic agents (e.g. sulphonylureas, insulin, or meglitinides).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In post marketing data and in controlled clinical studies, adverse event reporting in patients treated with Glucophage SR was similar in nature and severity to that reported in patients treated with Glucophage immediate release.<br />During treatment initiation, the most common adverse reactions are nausea, vomiting, diarrhoea, abdominal pain and loss of appetite, which resolve spontaneously in most cases.<br />The following adverse reactions may occur with Glucophage SR.<br />Frequencies are defined as follows: very common: &gt;1/10; common &ge;1/100, &lt;1/10; uncommon &ge;1/1,000, &lt;1/100; rare &ge;1/10,000, &lt;1/1,000; very rare &lt;1/10,000.<br />Within each frequency grouping, adverse reactions are presented in order of decreasing seriousness.<br />Metabolism and nutrition disorders<br />Very rare:<br />&bull; Lactic acidosis (see 4.4. Special warnings and precautions for use).<br />&bull; Decrease of vitamin B12 absorption with decrease of serum levels during long-term use of metformin. Consideration of such an aetiology is recommended if a patient presents with megaloblastic anaemia.<br />Nervous system disorders<br />Common:<br />&bull; Taste disturbance<br />Gastrointestinal disorders<br />Very common:<br />&bull; Gastrointestinal disorders such as nausea, vomiting, diarrhoea, abdominal pain and loss of appetite. These undesirable effects occur most frequently during initiation of therapy and resolve spontaneously in most cases. A slow increase of the dose may also improve gastrointestinal tolerability.<br />Hepatobiliary disorders<br />Very rare<br />&bull; Isolated reports of liver function tests abnormalities or hepatitis resolving upon metformin discontinuation.<br />Skin and subcutaneous tissue disorders<br />Very rare: &bull; Skin reactions such as erythema, pruritus, and urticaria.<br />To report any side effect(s):<br />&bull; Saudi Arabia:<br />- National Pharmacovigilance &amp; Drug Safety Centre (NPC):<br />&bull; Fax: +966-11-205-7662<br />&bull; Call NPC at +966-11-2038222, Ext.: 2317-2356-2353-2354-2334-2340.<br />&bull; Toll free phone : 8002490000<br />&bull; E-mail: npc.drug@sfda.gov.sa<br />&bull; Website: www.sfda.gov.sa/npc<br />- Other GCC States:<br />Please contact the relevant competent authority.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Hypoglycaemia has not been seen with metformin doses of up to 85 g, although lactic acidosis has occurred in such circumstances. High overdose or concomitant risks of metformin may lead to lactic acidosis. Lactic acidosis is a medical emergency and must be treated in hospital. The most effective method to remove lactate and metformin is hemodialysis</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: ORAL ANTI-DIABETICS (A10BA02: Gastrointestinal tract and metabolism) Metformin is a biguanide with antihyperglycaemic effects, lowering both basal and postprandial plasma glucose. It does not stimulate insulin secretion and therefore does not produce hypoglycaemia.<br />Mechanism of action<br />Metformin may act via 3 mechanisms:<br />&bull; Reduction of hepatic glucose production by inhibiting gluconeogenesis and glycogenolysis.<br />&bull; In muscle, by increasing insulin sensitivity, improving peripheral glucose uptake and utilization.<br />&bull; And delay of intestinal glucose absorption.<br />Metformin stimulates intracellular glycogen synthesis by acting on glycogen synthase.<br />Metformin increases the transport capacity of all types of membrane glucose transporters (GLUT).<br />Pharmacodynamic effects<br />In clinical studies, the major non glycemic effect of metformin is either weight stability or modest weight loss.<br />In humans, independently of its action on glycaemia, immediate release metformin has favorable effects on lipid metabolism. This has been shown at therapeutic doses in controlled, medium-term or long-term clinical studies: immediate release metformin reduces total cholesterol, LDL cholesterol and triglyceride levels. A similar action has not been demonstrated with the prolonged release formulation, possibly due to the evening administration, and an increase in triglycerides may occur.<br />Clinical efficacy:<br />Reduction in the risk or delay of type 2 diabetes mellitus<br />The Diabetes Prevention Program (DPP) was a multicenter randomised controlled clinical trial in adults assessing the efficacy of an intensive lifestyle intervention or metformin to prevent or delay the development of type 2 diabetes mellitus.<br />Inclusion criteria were age &ge;25 years, BMI &ge;24 kg/m2 (&ge;22 kg/m2 for Asian-Americans), and impaired glucose tolerance plus a fasting plasma glucose of 95 &ndash; 125 mg/dl (or &le;125 mg/dl for American Indians). Patients were either treated with intensive lifestyle intervention, 2x850 mg metformin plus standard lifestyle change, or placebo plus standard lifestyle change.<br />The mean baseline values of the DPP participants (n=3,234 for 2.8 years) were age 50.6&plusmn;10.7 years, 106.5&plusmn;8.3 mg/dl fasted plasma glucose, 164.6&plusmn;17.0 mg/dl plasma glucose two hours after an oral glucose load, and 34.0&plusmn;6.7 kg/m2 BMI.<br />Intensive lifestyle intervention as well as metformin significantly reduced the risk of developing overt diabetes compared to placebo, 58% (95% CI 48-66%) and 31% (95% CI 17-43%), respectively.<br />The advantage of the lifestyle intervention over metformin was greater in older persons.<br />The patients who benefited most from the metformin treatment were aged below 45 years, with a BMI equal or above<br />35kg/m2, a baseline glucose 2 h value of 9.6-11.0 mmol/l, a baseline HbA1C equal or above 6.0% or with a history of gestational diabetes.<br />To prevent one case of overt diabetes during the three years in the whole population of the DPP, 6.9 patients had to participate in the intensive lifestyle group and 13.9 in the metformin group. The point of reaching a cumulative incidence of diabetes equal to 50% was delayed by about three years in the metformin group compared to placebo.<br />The Diabetes Prevention Program Outcomes Study (DPPOS) is the long-term follow-up study of the DPP including no more than 87% of the original DPP population for long-term follow up.<br />Among the DPPOS participants (n=2776), the cumulative incidence of diabetes at year 15 is 62% in the placebo group, 56% in the metformin group, and 55% in the intensive lifestyle intervention group. Crude rates of diabetes are 7.0, 5.7 and 5.2 cases per 100 person‐years among the placebo, metformin, and intensive lifestyle participants, respectively.<br />Reductions in the diabetes risk were of 18% (hazard ratio (HR) 0.82, 95% CI 0.72&ndash;0.93; p=0.001) for the metformin group and 27% (HR 0.73, 95% CI 0.65&ndash;0.83; p&lt;0.0001) for the intensive lifestyle intervention group, when compared with the placebo group. For an aggregate<br />microvascular endpoint of nephropathy, retinopathy and neuropathy, the outcome was not significantly different between the treatment groups, but among the participants who had not developed diabetes during DPP/DPPOS, the prevalence of the aggregate microvascular outcome was 28% lower compared with those who had developed diabetes (Risk Ratio 0.72, 95% CI 0.63&ndash;0.83; p&lt;0.0001). No prospective comparative data for metformin on macrovascular outcomes in patients with IGT and/or IFG and/or increased HbA1C are available.<br />Published risk factors for type 2 diabetes include: Asian or black ethnic background, age above 40, dyslipidaemia, hypertension, obesity or being overweight, age, 1st degree family history of diabetes, history of gestational diabetes mellitus, and polycystic ovary syndrome (PCOS).<br />Consideration must be given to current national guidance on the definition of prediabetes.<br />Patients at high risk should be identified by a validated risk-assessment tool.<br />Treatment of type 2 diabetes mellitus<br />The prospective randomised (UKPDS) study has established the long-term benefit of intensive blood glucose control in overweight type 2 diabetic patients treated with immediate release metformin as first-line therapy after diet failure.<br />Analysis of the results for overweight patients treated with metformin after failure of diet alone showed:<br />&bull; a significant reduction of the absolute risk of any diabetes-related complication in the metformin group (29.8 events/<br />1000 patient-years) versus diet alone (43.3 events/ 1000 patient-years), p=0.0023, and versus the combined sulphonylurea and insulin monotherapy groups (40.1 events/ 1000 patient-years), p=0.0034.<br />&bull; a significant reduction of the absolute risk of diabetes-related mortality: metformin 7.5 events/1000 patient-years, diet alone 12.7 events/ 1000 patient-years, p=0.017;<br />&bull; a significant reduction of the absolute risk of overall mortality: metformin 13.5 events/ 1000 patient-years versus diet alone 20.6 events/ 1000 patient-years (p=0.011), and versus the combined sulphonylurea and insulin monotherapy groups 18.9 events/ 1000 patient-years (p=0.021);<br />&bull; a significant reduction in the absolute risk of myocardial infarction: metformin 11 events/ 1000 patient-years, diet alone 18 events/ 1000 patient-years (p=0.01) For metformin used as second-line therapy, in combination with a sulphonylurea, benefit regarding clinical outcome has not been shown.<br />In type 1 diabetes, the combination of metformin and insulin has been used in selected patients, but the clinical benefit of this combination has not been formally established.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: ORAL ANTI-DIABETICS (A10BA02: Gastrointestinal tract and metabolism) Metformin is a biguanide with antihyperglycaemic effects, lowering both basal and postprandial plasma glucose. It does not stimulate insulin secretion and therefore does not produce hypoglycaemia.<br />Mechanism of action<br />Metformin may act via 3 mechanisms:<br />&bull; Reduction of hepatic glucose production by inhibiting gluconeogenesis and glycogenolysis.<br />&bull; In muscle, by increasing insulin sensitivity, improving peripheral glucose uptake and utilization.<br />&bull; And delay of intestinal glucose absorption.<br />Metformin stimulates intracellular glycogen synthesis by acting on glycogen synthase.<br />Metformin increases the transport capacity of all types of membrane glucose transporters (GLUT).<br />Pharmacodynamic effects<br />In clinical studies, the major non glycemic effect of metformin is either weight stability or modest weight loss.<br />In humans, independently of its action on glycaemia, immediate release metformin has favorable effects on lipid metabolism. This has been shown at therapeutic doses in controlled, medium-term or long-term clinical studies: immediate release metformin reduces total cholesterol, LDL cholesterol and triglyceride levels. A similar action has not been demonstrated with the prolonged release formulation, possibly due to the evening administration, and an increase in triglycerides may occur.<br />Clinical efficacy:<br />Reduction in the risk or delay of type 2 diabetes mellitus<br />The Diabetes Prevention Program (DPP) was a multicenter randomised controlled clinical trial in adults assessing the efficacy of an intensive lifestyle intervention or metformin to prevent or delay the development of type 2 diabetes mellitus.<br />Inclusion criteria were age &ge;25 years, BMI &ge;24 kg/m2 (&ge;22 kg/m2 for Asian-Americans), and impaired glucose tolerance plus a fasting plasma glucose of 95 &ndash; 125 mg/dl (or &le;125 mg/dl for American Indians). Patients were either treated with intensive lifestyle intervention, 2x850 mg metformin plus standard lifestyle change, or placebo plus standard lifestyle change.<br />The mean baseline values of the DPP participants (n=3,234 for 2.8 years) were age 50.6&plusmn;10.7 years, 106.5&plusmn;8.3 mg/dl fasted plasma glucose, 164.6&plusmn;17.0 mg/dl plasma glucose two hours after an oral glucose load, and 34.0&plusmn;6.7 kg/m2 BMI.<br />Intensive lifestyle intervention as well as metformin significantly reduced the risk of developing overt diabetes compared to placebo, 58% (95% CI 48-66%) and 31% (95% CI 17-43%), respectively.<br />The advantage of the lifestyle intervention over metformin was greater in older persons.<br />The patients who benefited most from the metformin treatment were aged below 45 years, with a BMI equal or above<br />35kg/m2, a baseline glucose 2 h value of 9.6-11.0 mmol/l, a baseline HbA1C equal or above 6.0% or with a history of gestational diabetes.<br />To prevent one case of overt diabetes during the three years in the whole population of the DPP, 6.9 patients had to participate in the intensive lifestyle group and 13.9 in the metformin group. The point of reaching a cumulative incidence of diabetes equal to 50% was delayed by about three years in the metformin group compared to placebo.<br />The Diabetes Prevention Program Outcomes Study (DPPOS) is the long-term follow-up study of the DPP including no more than 87% of the original DPP population for long-term follow up.<br />Among the DPPOS participants (n=2776), the cumulative incidence of diabetes at year 15 is 62% in the placebo group, 56% in the metformin group, and 55% in the intensive lifestyle intervention group. Crude rates of diabetes are 7.0, 5.7 and 5.2 cases per 100 person‐years among the placebo, metformin, and intensive lifestyle participants, respectively.<br />Reductions in the diabetes risk were of 18% (hazard ratio (HR) 0.82, 95% CI 0.72&ndash;0.93; p=0.001) for the metformin group and 27% (HR 0.73, 95% CI 0.65&ndash;0.83; p&lt;0.0001) for the intensive lifestyle intervention group, when compared with the placebo group. For an aggregate<br />microvascular endpoint of nephropathy, retinopathy and neuropathy, the outcome was not significantly different between the treatment groups, but among the participants who had not developed diabetes during DPP/DPPOS, the prevalence of the aggregate microvascular outcome was 28% lower compared with those who had developed diabetes (Risk Ratio 0.72, 95% CI 0.63&ndash;0.83; p&lt;0.0001). No prospective comparative data for metformin on macrovascular outcomes in patients with IGT and/or IFG and/or increased HbA1C are available.<br />Published risk factors for type 2 diabetes include: Asian or black ethnic background, age above 40, dyslipidaemia, hypertension, obesity or being overweight, age, 1st degree family history of diabetes, history of gestational diabetes mellitus, and polycystic ovary syndrome (PCOS).<br />Consideration must be given to current national guidance on the definition of prediabetes.<br />Patients at high risk should be identified by a validated risk-assessment tool.<br />Treatment of type 2 diabetes mellitus<br />The prospective randomised (UKPDS) study has established the long-term benefit of intensive blood glucose control in overweight type 2 diabetic patients treated with immediate release metformin as first-line therapy after diet failure.<br />Analysis of the results for overweight patients treated with metformin after failure of diet alone showed:<br />&bull; a significant reduction of the absolute risk of any diabetes-related complication in the metformin group (29.8 events/<br />1000 patient-years) versus diet alone (43.3 events/ 1000 patient-years), p=0.0023, and versus the combined sulphonylurea and insulin monotherapy groups (40.1 events/ 1000 patient-years), p=0.0034.<br />&bull; a significant reduction of the absolute risk of diabetes-related mortality: metformin 7.5 events/1000 patient-years, diet alone 12.7 events/ 1000 patient-years, p=0.017;<br />&bull; a significant reduction of the absolute risk of overall mortality: metformin 13.5 events/ 1000 patient-years versus diet alone 20.6 events/ 1000 patient-years (p=0.011), and versus the combined sulphonylurea and insulin monotherapy groups 18.9 events/ 1000 patient-years (p=0.021);<br />&bull; a significant reduction in the absolute risk of myocardial infarction: metformin 11 events/ 1000 patient-years, diet alone 18 events/ 1000 patient-years (p=0.01) For metformin used as second-line therapy, in combination with a sulphonylurea, benefit regarding clinical outcome has not been shown.<br />In type 1 diabetes, the combination of metformin and insulin has been used in selected patients, but the clinical benefit of this combination has not been formally established.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Preclinical data reveal no special hazard for humans based on conventional studies on safety pharmacology, repeated dose toxicity, genotoxicity, carcinogenic potential, toxicity reproduction.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Carboxy Methyl Cellulose Na<br />Hydroxypropyl Methyl Cellulose (Methocel E5)<br />Hydroxypropyl Methyl Cellulose (Methocel K1000)<br />Magnesium Stearate</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                2 years
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Don&rsquo;t store above 30 ْC</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>DIAPHAGE&reg; SR 1000 mg Tablets packed in PVC/Aluminum foil, in carton box with a folded leaflet, in pack size of 30 tablets.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Any unused product or waste should be disposed of in accordance with local requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                United Pharmaceutical Company
Tel: 00962 6 4162901
Fax: 00962 6 4162905
E-mail: info@upm.com.jo
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                May. 2017
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>